

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-100195-PIP01-21-M02

### **Scope of the Application**

#### **Active Substance(s)**

BALOXAVIR MARBOXIL

#### **Condition(s)**

Treatment of Influenza, Prevention of Influenza

#### **Pharmaceutical Form(s)**

Film-coated tablet; Granules for oral suspension.

#### **Route(s) of Administration**

ORAL USE

#### **Name / Corporate name of the PIP applicant**

Roche Products Limited

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Roche Products Limited submitted to the licensing authority on 09/05/2022 18:47 BST an application for a Modification

The procedure started on 25/11/2022 14:16 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100195-PIP01-21-M02

Of 13/01/2023 15:01 GMT

On the adopted decision for BALOXAVIR MARBOXIL (MHRA-100195-PIP01-21-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for BALOXAVIR MARBOXIL, Film-coated tablet Granules for oral suspension. , ORAL USE .

This decision is addressed to Roche Products Limited, 6 Falcon Way, Shire Park,, Welwyn Garden City, UNITED KINGDOM, AL7 1TW

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Not applicable to the Treatment of influenza or the Prevention of influenza.

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of influenza; Prevention of influenza

#### 2.2 Indication(s) targeted by the PIP:

Treatment of influenza. Post-exposure prophylaxis.

### 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age.

### 2.4 Pharmaceutical Form(s):

Film-coated tablet Granules for oral suspension

### 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable
Non-Clinical Studies	0	Not applicable
Clinical Studies	4	Study 1 (CP40559) Multicentre, single-arm, open-label study to assess safety, pharmacokinetics, and efficacy of baloxavir marboxil in infants from birth to less than 1 year of age with influenza-like symptoms. Study 2 (CP40563) Multicentre, randomised, double-blind, active-controlled study to assess the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared to oseltamivir in children from 1 year to less than 12 years of age with influenza-like symptoms. Study 3 (CP40617) Randomised, double-blind, placebo-controlled, multicentre study to assess efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard of care neuraminidase inhibitor (SOC NAI), compared with a matching placebo in combination with a SOC NAI in adolescents who require hospitalisation for severe influenza, or who contract severe influenza during hospitalisation (and adults). Study 4 was removed during procedure EMEA-002440-PIP01-18-M01. Study 13 Randomised, double-blind, multicentre, parallel-group, placebo-controlled comparative study to evaluate the efficacy and safety of a single oral dose of baloxavir

		marboxil in the prevention of influenza virus infection in paediatric subjects from birth to less than 18 years of age who are household members of influenza-infected index patients.
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	4	Study 5 (M&S Study 1) Population PK model in otherwise healthy and high-risk adult and paediatric subjects, evaluating relevant demographic covariates that may influence systemic drug exposure. Study 6 was removed during procedure EMEA-002440-PIP01-18-M01. Study 7 (M&S Study 3) Modelling and simulation study in Otherwise Healthy and High-risk patients evaluating exposure-response using viral kinetic modelling and primary efficacy endpoints. Study 8 was removed during procedure EMEA-002440-PIP01-18-M01. Study 9 was removed during procedure EMEA-002440-PIP01-18-M01. Study 10 (Extrapolation study 1) Partial extrapolation of PK, PD (virology, virus titres) and efficacy (primary endpoint, time to symptom alleviation) in otherwise healthy paediatric patients from birth to less than 12 years of age. Study 11 (Extrapolation study 2) Complete extrapolation of PD and efficacy (primary endpoint, time to symptom alleviation) in High-Risk paediatric patients from birth to less than 12 years of age. Study 12 was removed during procedure EMEA-002440-PIP01-18-M01.
<b>Other Studies</b>	0	Not applicable
<b>Other Measures</b>	0	Not applicable

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	No
<b>Date of completion of the paediatric investigation plan:</b>	31/12/2024
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes

